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B cell stimulatory factor 1 (BSF-I)' is a 20 kD murine T cell-derived glyco-
protein that was first described as a costimulant of B cell entry into S phase in
response to anti-Ig antibodies (I) . BSF-1 also induces resting B cells to increase
their expression of class II major histocompatibility complex (MHC) molecules
(2, 3) and markedly promotes the secretion of IgG1 and IgE by lipopolysaccharide
(LPS)-stimulated B cells (4-7). BSF-I has been purified to homogeneity by affinity
chromatography and high pressure liquid chromatography (8, 9, and Ohara,
Maloy, Coligan, Zoon, and Paul ; manuscript submitted for publication) and
cDNA clones for murine BSF-I (10, 11) and for its human analogue (12) have
been obtained. A monoclonal anti-BSF-I antibody that inhibits its biological
activities has been derived (13) . Recently, BSF-1 has been shown to cause
proliferation of long-term T cell lines, such as HT-2 cells (9, 14, 15) and to
enhance the capacity of interleukin 3 to stimulate the growth of mast cell lines
(14). These results indicate that the range of action of BSF-1 is not limited to B
cells. The designation interleukin-4 (IL-4) has been proposed for BSF-1 (10).
In this manuscript, we show that BSF-I together with phorbol myristate acetate
(PMA) stimulates resting T cells to enter the S phase of the cell cycle and to
proliferate. Its action does not require accessory cells and is density independent.
Virtually all normal T cells respond to BSF-I plus PMA asjudged by increase in
cell volume. BSF-I is required early in the T cell response, suggesting that it acts
on resting T cells in a manner analogous to its action on resting B cells (16-18).
However, BSF-1 is also necessary in the later phase (24-48 h) of the response of
T cells to BSF-1 plus PMA. BSF-1 may prove to be of considerable importance
in the physiologic activation of T cells, particularly in recruitment of T cell
division in the environment of activated BSF-I-producing T cells, and possibly
as an autocrine stimulatory factor.
Materials and Methods
Animals.
￿
Virus-free BALB/c and DBA/2 female mice, 8-12 wk of age, were obtained
from Biological Testing Branch of the National Cancer Institute, Frederick Cancer
Research Facility, Frederick, MD.
' Abbreviationsused in this paper:
￿
BSF-1, B cell stimulatory factor 1; PI, propidium iodine; PKC,
protein kinase C; PMA, phorbol myristate acetate.
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CultureMedium.
￿
RPMI 1640 (Biofluids, Rockville, MD) supplemented with 10% FCS
(Biofluids, Rockville, MD), L-glutamine (2 mM), 2-ME (0.05 MM), penicillin (50 ag/ml),
and streptomycin (50,ug/ml) was used for culturingcells.
Reagents andMonoclonal Antibodies.
￿
A23187, phorbol-12-myristate-13-acetate (PMA),
and propidium iodide (PI) were purchased from Sigma Chemical Company, St. Louis,
MO. Con A and Percoll were obtained from Pharmacia Fine Chemicals, Piscataway, NJ.
Recombinant mouse 0 interleukin 1 (IL-1) was from Hoffman-LaRoche, Nutley, NJ.
Purified mouse interleukin 3 (IL-3) waskindly provided by Dr. James Ihle, NCI-Frederick
Cancer Research Facility (19). Recombinant human interleukin 2 (IL-2) was from Cetus
Corporation, Emeryville, CA. Recombinant mouse IFN--y was generously provided by
Genentech, Inc., South San Francisco, CA. Monoclonal rat IgGI anti-BSF-1 antibody
11 B11 (13) and monoclonal rat IgG2a anti-IL-2 antibody S4B6.1 (14) were used as diluted
ascitic fluids. Monoclonal rat IgG2a antidinitrophenyl (DNP) antibody (50C1), prepared
from cells obtained from Dr. Joseph Davie, Washington University, St. Louis, MO served
as a control ascitic fluid for lIBI I and S4B6 .1 (20). Goat anti-mouse IgM heavy chain-
specific antibody used in panning were prepared and purified in our laboratory (21).
Preparation of T Cells.
￿
Purified T cells were prepared from mesenteric lymph nodes
by two nylon wool column passages and subsequent cytolysis with an anti-la monoclonal
antibody (M5114; American Type Culture Collection, Rockville, MD) (22) plus low-tox-
M rabbit complement (Cederlane Laboratories, Hornby, Ontario, Canada). To obtain
purified L3T4+or Lyt-2+ cells, monoclonal anti-Lyt-2 antibody (23) or anti-L3T4antibody
(24) plus MAR 18.5 mouseanti-rat Kantibody (25) wasaddedto theantibody-complement
cocktail. In some cases, the cells were further purified by depletion of IgM-bearing cells
by an anti-IgM panning method (26). Small dense resting T cells were then separated by
a modified discontinuous Percoll gradient procedure (27). Purified T cells that were
included in the 66-70% band were considered to be small resting T cells. In selected
cases, cells were incubated with a mixtureof fluoresceinated anti-L3T4 (GK1 .5) and anti-
Lyt-2 (53.6.7). The 20% most intensely fluorescent cells were then obtained by electronic
cell sorting using an EPICS V (Coulter Electronics, Hialeah, FL).
Preparation of BSF-1.
￿
BSF-1 was purified from supernatant fluids (SN) of EL-4 cells
that had been induced with PMA. The SN was first passed over an anti-BSF-1 affinity
column and the bound material was eluted with 0.1 % trifluoracetic acid. The eluate was
applied to a C18 reverse-phase high performance liquid chromatography column. BSF-1
obtained in this manner contained one major protein of 20,000 M, on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis. Its biological activities were inhibited by
monoclonal anti-BSF-I antibody.
One unit of BSF-1 is defined as the amount of BSF-1 required for half-maximal
stimulation of ['H]thymidine uptake by resting B cells stimulated with 5 ug/ml of goat
anti-IgM antibody (1).
Cell Culture.
￿
Functional assays were carried out in 96-well flat-bottom Costar plates,
in triplicate, with 200,ul final volume. The plates were incubated at 37°C in ahumidified
6% C02 atmosphere. DNA synthesiswasdetermined by ['H]thymidineuptake (1 ACi/well,
6.7 Ci/nmol; [ICN, Irvine, CA]) after a 16-h labeling. For time-course experiments, a 4-
h labeling time was used. Cells were harvested onto glass filter paper and [5H]thymidine
incorporation was determined by liquid scintillation spectrometry.
Cell CycleAnalysis.
￿
Cells were cultured at a concentration of 2.5 X 105 cells/ml in 24-
well Costar plates. Colcemid (25 ng/ml) was added 20 h after the initiation of culture.
Cultures were terminated at 48 h, and viable cell number was determined. Cells (106)
were pelleted and the pellet was resuspended with hypotonic PI (0.1% sodium citrate,
0.1 % Triton X (vol/vol) and 0.05 mg/ml PI made up in double distilled water). DNA
content was determined by measuring PI fluorescence (28, 29) using a FRCS analyzer
(Becton-Dickinson Immunocytometry Systems, Mountain View, CA).
Volume Analysis.
￿
Cell volumes were measured with a Coulter Counter (Model ZB1)
and Coulter Channelizer L (C-1000; Coulter Electronics). 4 X 104 cells were counted to
obtain histograms.
Determination of [Ca21],.
￿
Intracellular free calcium concentration ([Ca21],) in T cellsHU-L1 ET AL.
￿
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in response to BSF-1 and/or PMA was determined as previously described using the
fluorescent calcium-binding dye Quin 2 (30).
Results
BSF-1 Acts on Highly Purified T Cells.
￿
To investigate the activity of BSF-1 on
T cells, mesenteric lymph node cells were purified by an extensive procedure
involvingtwo rounds of passage over nylon wool, treatment with anti-la antibod-
ies and complement, and depletion of IgM-bearing cells by panning on anti-
IgM-coated dishes. The resultant cells were then centrifuged on a discontinuous
Percoll density gradient to obtain small cells. These were then stained with a
mixture of fluoresceinated anti-L3T4 and Lyt-2 antibodies. Fluorescent cells
were obtained by electronic cell sorting.
These highly purified small T cells showed a striking response to BSF-1 plus
PMA, yielding incorporation of [3H]thymidine comparable to that observed in
response to PMA plus the calcium ionophore A23187 (Table IA). Neither BSF-
1 nor PMA alone caused any detectable DNA synthesis. It should be noted that
many conventional T cell stimulants, such as Con A, fail to stimulate T cells
purified to this degree. Indeed, purified T cellsdeveloped very meager responses
to Con A plus PMA (Table IA).
Thepossibility that the costimulatoryactivity of the purified BSF-1 preparation
might be due to contamination with IL-2 was addressed by examining the
inhibitory capacity of monoclonal anti-BSF-1 and anti-IL-2 antibodies. Small
BALB/c lymph node T cells were purified by passage over nylon wool treatment
with anti-la antibodies and complement and centrifugation on a discontinuous
Percoll density gradient. The response of these cells to BSF-1 plus PMA was
completely inhibited by the monoclonal anti-BSF-1 antibody 11 B11 but was not
affected either by the monoclonal anti-IL-2 antibody S4B6.1 or by the monoclo-
nal anti-DNP antibody 50C1 (Table IB) . These results indicate that the costi-
mulatory activity of purified BSF-1 was a property of BSF-1 itself. In other
experiments, PC 61 (31), a monoclonal rat IgGI anti-IL-2 receptor antibody
failed to inhibit responses ofT cells to purified BSF-1 and PMA (data not shown).
These resultsprovided further supportfor the conclusion that it was BSF-1 itself,
and not a putative IL-2 contaminant, which was responsible for the stimulation.
Furthermore, PC 61 provides a class-matched control for 11B11, which is also a
rat IgG1.
Although the T cells used in these experiments were very extensivelypurified,
it is possible that the small number of B cells that might remain contributed to
this response, possibly by becoming efficient accessory cells as a result of stimu-
lation by BSF-1. We reasoned that if B cellswere essential for the T cell responses
to BSF-1 plus PMA, the addition of resting B cells to a highly purified T cell
population might cause striking enhancement of its response. As shown in Table
IC, addition of purified B cells in amounts far in excess of the number of B cells
that mightpossibly remain in the T cell population had no effect on the response
to BSF-1 plus PMA. These experiments provide strong evidence that the BSF-1
effect is mediated by direct action on T cells.
The response of T cells to BSF-1 plus PMA was dependent on the BSF-1
concentration used. Maximal responses were obtained with 10-30 U/ml (Fig. 1)160
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TABLE I
TCells Synthesize DNA in Response to BSF-1 +PMA
B. Inhibition by Anti-BSF-I
Monoclonal
antibody
Stimulant
Dilution
['H]Thymidine uptake (cpm)in response
to:
Medium BSF-I (100
￿
BSF-I (1,000
U/ml)+ PMA U/ml) + PMA
None
￿
280 54,100 172,200
Anti-BSF-1 1:1,000 180 200 2,700
Anti-BSF-I 1:300 210 210 550
Anti-IL-2 1:1,000 240 53,100 166,500
Anti-IL-2 1:300 190 55,900 194,600
Anti-DNP 1:1,000 180 70,500 154,300
Anti-DNP 1 :300 330 69,700 146,700
C. Adding B Cells Does Not Increase the Response
['H]Thymidine uptake (cpm)
B cells:
￿
0
￿
102 ￿10'
￿
10'
(A) Highly purified T cells respond to BSF-1 plus PMA. BALB/c lymph node
cells were purified by two passes over nylon wool, lysis with anti-la + C, and
panningto deplete IgM+ cells. Theremainingcellswere then subjectedto Percoll
gradient centrifugation; thesmallrestingTcellsbandingat theinterface between
66-70% Percoll were retained. Thesecellswere then stained with fluoresceinated
anti-L3T4andanti-Lyt-2 and fluorescent cellsobtained by electronic cell sorting.
Sorted cells were cultured in 96-well flat-bottom plates at 2.5 X 10' cells/well.
['H]Thymidine wasaddedat 48 h andthecells were harvestedat 64 h ofculture.
(B) Small T cells were prepared from mesenteric lymph nodes by passageover
nylon wool, cytolysis with anti-la andC, and Percoll density gradient centrifuga-
tion. T cells were incubated at 2.5 X 10' cells/well with medium or BSF-1 plus
PMA (I ng/ml) in the presence of ascitic fluid containing the monoclonal rat
antibodies 111311 (anti-BSF-1), S4B6.1 (anti-IL-2), or 50C.1 (anti-DNP). ['H]
Thymidine was added at 48 h, and the cellswere harvested at 64 h of culture.
(C) Resting BALB/c spleen cellswere treated with anti-Thy-1.2,anti-Lyt-1, and
anti-Lyt-2 monoclonal antibodies followed by MAR 18.5 andcomplement. Dense
B cells were obtained by Percoll density gradient centrifugation. Resting mes-
enteric lymph node Tcells were prepared by twopasses over nylon wool,cytolysis
with anti-la and C, panning with anti-IgM, and Percoll density gradient centrif-
ugation. T cells were incubated at 2.5 X 10' cells/well with added B cells, at
various densitiesfrom 0 to 10' cells/well. ['H]Thymidine was added at 48 h and
thecells were harvested at 64 h of culture.
indicating that Tcell responses to BSF-1 requiresomewhat higher concentrations
than do B cell responses, where costimulation with anti-IgM is half-maximal at 1
U/ml (8). Essentially equivalent T cell responses are obtained with PMA concen-
trations of 1 ng/ml and 10 ng/ml (data not shown).
RPMI 379 373 331 872
BSF-1 (30 U/ml) 604 361 342 1,310
PMA (10 ng/ml) 702 259 211 510
PMA + BSF-1 28,064 31,929 30,926 25,128
A. Highly Purified T Cells
Stimulant
['H]Thymidine
-PMA
uptake (cpm)
+PMA (10 ng/ml)
RPMI 396 396
BSF-I (30 U/ml) 463 108,113
A23187 (100 ng/ml) ND 98,465
Con A (3 Ag/ml) 396 3,3312
HU-L1 ET AL.
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FIGURE 1 . BSF-1 concentration/response curve. BALB/c mesenteric lymph node T cells
were prepared by two rounds of passage over nylon wool, complement-mediated lysis to
remove la-bearing cells, and Percoll density gradient centrifugation to obtain small, dense T
cells. Cells were then cultured with various concentrations of BSF-1 at 5 X 104 cells/well in
96-well flat-bottom plates. [sH]Thymidine was added at 48 h and cells were harvested at 64
h.
BSF-1 and PMA Stimulates Both L3T4' and Lyt-2+ Cells in a Density-independent
Manner. To gain further insight regarding the possible role of cellular inter-
actions in the response of T cells to BSF-1 and PMA, we examined the density
dependence of this response. Purified small T cells were cultured at densities
from 7.8 X 102 cells/well to 2.5 X 104 cells/well. Over this range the T cell
response to BSF-1 plus PMA was essentially density independent (Fig. 2). The
slope ofthe line relating the logof [sH]thymidine incorporation to the log ofthe
number of cells cultured was 0.96 ± 0.12, with a correlation coefficient (r2) of
0.97. Even at the lowest density (7.8 X 102 cells/well), BSF-1 plus PMA caused
a significant stimulation ofT cells over the response to medium, BSF-1 alone, or
PMA alone. This result strongly suggests that the T cell response to BSF-1 plus
PMA does not depend on accessory cells, since the interaction of two or more
cell types should be expected to yield a line with a log cell number/log response
slope >1 .0. Indeed, the T cells used in this experiment had been purified to an
extent that the actual number ofnon-T cells in populations culturedatthe lowest
density (7.8 X 102 cells/well) was very small, probably <20.
In the experiment shown in Fig. 2, right, purified T cells treated with anti-Lyt-
2 and C (L3T4+) or with anti-L3T4 and C (Lyt-2+) were cultured at various
densities with BSF-I plus PMA. For both populations, the slope relating the log
cell number and the log response approached 1 . Lyt-2+ cells responded approx-
imately threefold more vigorously than L3T4+ cells. It is very unlikely that the
response of the L3T4+ cells could be due to residual Lyt-2+ T cells, because this162
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FIGURE 2.
￿
T cell responses to PMA + BSF-1 are density independent. Small dense BALB/c
T cells (left), L3T4* and Lyt-2` DBA/2 T cells (right) were cultured with BSF-1 (30 U/ml)
and PMA (1 ng/ml) at various densities for 64 h. ['H]Thymidine was added for the last 16 h
of culture. Cell number per well and ['H]thymidine uptake (cpm) were plotted on a log/log
scale. Slopes and correlation coefficients (r2) were determined by linear regression analysis.
Controls for response to BSF-1 plus PMA were PMA alone(1 ng/ml), BSF-1 alone (30 U/ml),
and medium only. The PMA alone curve for BALB/c T cells is shown forillustration; each of
theother control responses were comparable.
would require a content of one-third Lyt-2+ T cells in the L3T4+ population .
This is a proportion of Lyt-2+ T cells that exceeds their frequency in the starting
cell population, where it is 15-20%.
BSF-1 Plus PMA Leads to T Cell Growth.
￿
The effect of BSF-1 plus PMA on
resting T cell populations is not limited to causing entry into S phase, but also
causes actual proliferation of these cells. Small T cells were cultured with BSF-1
plus PMA for 5-6 dand the yield of living cells and [3H]thymidine incorporation
was measured on each day. The number of viable cells recovered from cultures
containing BSF-1 plus PMA fell over the first two days from 2.5 X 10' (the
number of cells seeded) to 1.1 X 10' (Fig. 3). Thereafter, the yield of living cells
increased with a doubling time of ^-24 h, reaching 7.6 X 10' cells/well on day 5.
The yield of living cells from cultures containing PMA plus A23187 was essen-
tially the same as that from cultures containing BSF-1 plus PMA. Cultures
containing medium alone showed progressive cell death over the duration of the
culture, reaching 0.4 X 10' cells/well on day 5. PMA accelerated the rate of cell
loss. Strikingly, cultures treated with BSF-1 alone maintained good viability over
the duration of the culture, falling from 2.5 X 10' cells/well at the outset to 1.5
X 10' at day 5. Since these cells incorporated essentially no thymidine over this
period, we conclude that treatmentof restingTcells with BSF-1 alone maintained
their viability. In turn, this indicates that BSF-1 acts on resting T cells.
This viability-promoting activity of BSF-1 does not appear to be associated
with any gross activation of the T cells. Over a 48-h period, T cells cultured with
BSF-1 alone remain small. Fig. 4 shows results of a 24-h culture of T cells.
Purified small T cells cultured in medium alone or in BSF-1 are a homogeneous
population of small cells at 24 h (median cell volume, 113-120 Am'). PMA causes
a small increase in the volume of these cells, but BSF-1 plus PMA causes aHU-LI ET AL.
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￿
T cell responses to PMA + BSF-1 and to BSF-1. Dense BALB/c T cells were
cultured at 2.5 X 10' cells/well in medium alone (RPMI), BSF-1 (30 U/ml), PMA (1 ng/ml),
PMA plus BSF-1, or PMA plus A23187 (100 ng/ml). Yield of viable cells (left) and uptake of
[sH]thymidine during a 4-h pulse (right) are shown.
considerably more striking increase; such T cells have a median volume of 196
Am'. What is particularly interesting is that the entire size histogram of the T
cell population treated with BSF-1 plus PMA is displaced in comparison to that
of the T cell population treated with PMA alone, implying that virtually all
resting T cells are responsive to costimulation by these agents.
Further demonstration that BSF-1 plus PMA acts on a significant proportion
ofT cells was obtained by measuring the percent of T cells in the S, G2, and M
phases of the cell cycle at 48 h after stimulation with BSF-1 plus PMA (Table
11). At this time, 58% of the surviving cells are in S, G2, or M, emphasizing that
the action of BSF-1 plus PMA is not confined to a small subpopulation ofTcells.
BSF-I Is Required Both in the Early and Late Phases of the Initial Response of T
Cells. BSF-1 has been shown to act on resting B cells to enhance expression of
class 11 MHC molecules (2, 3) and to prepare these cells to enter S phase more
promptly in response to high concentrations ofanti-Ig antibodies or to LPS (16-
18). We therefore tested the time requirements of BSF-1 and of PMA in the
response of resting T cells. T cells were cultured for 24 h in medium, BSF-1,
PMA, or BSF-1 plus PMA. To thecells precultured in medium for 24 h, medium,
PMA, BSF-1, or BSF-1 plus PMA were added. These cells failed to respond to
PMA or to BSF-1. They did respond to PMA plus BSF-1 (Fig. 5), but only at 48
h of secondary culture, indicating that the initial cohort of cells responding to164 B CELL STIMULATORY FACTOR 1 ACTS ON RESTING T CELLS
Stimulant
RPMI
￿
120
SSF-1 (30U/ml)
￿
113
PMA(10n9/ml) 140
PMA + BSF-1
￿
198
PMA + A23187
￿
244
CELL VOLUME (Rel. Units)
FIGURE 4.
￿
BSF-1 plus PMA causes T cell enlargement. DenseBALB/c T cellswere cultured
for 24 h at 2.5 x 105 cells/ml/well in medium (RPMI), BSF-1 (30 U/ml), PMA (10 ng/ml),
BSF-1 plus PMA, or PMA plus A23187 (100 ng/ml). Cell volume was measured at the
termination of culture.
TABLE 11
MedianCell
Stimulant Volume
(wM3)
Cells in S, G2, andMPhases at 48 h in Response to BSF-1 + PMA
Cells in S, G2 and M
(%)
Smallresting T cellswere prepared by two rounds of passage over nylon
wool, treatment with anti-la plus C, and Percoll density centrifugation.
These cells were cultured at 2.5 x 105 cells/ml for 48 h with various
stimulants. Colcemid was added 20 h after initiation of assay. Cells were
pelleted at 106 cells/tube and resuspended in hypotonic PI. Suspended
nucei were analyzed for DNA contentafter 24 hat 4°C.
BSF-1 plus PMA does not enter S phase until after 24 h. By contrast, cells
precultured in BSF-1 plus PMA and then cultured with the same stimulants
during the secondary culture showed a striking response at 24 h and an even
greater response at 48 h. We then asked whether preculture in either BSF-1 or
in PMA would prepare cells to respond at 24 h of secondary culture in BSF-1
plus PMA. Asshown in Fig. 5, neither BSF-1 or PMA preculture accelerated the
response of these cells to PMA plus BSF-1, indicating that both agents were
required from the outset of the culture. Thus, BSF-1 is required early in the
first round ofTcell proliferation to PMA plus BSF-1.
BSF-1 is also required in the latter phases ofthe T cell response to BSF-1 plus
RPMI 4.0
BSF-1 (30 U/ml) 7.2
PMA (10 ng/ml) 10.9
BSF-1 + PMA 57.9
A23187 (100 ng/ml) + PMA 63.2M
X
Q
G)
Y
f0 r a
d c
.E
z
F2
M
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FIGURE 5.
￿
Both BSF-1 and PMAare required early in culture. Dense BALB/c Tcells were
precultured for 24 h at 2.5 X 10' cells/well, in medium (four sets of replicates), BSF-1 (30
U/ml) (two sets of replicates), PMA (1 ng/ml) (two sets of replicates) or BSF-1 plus PMA.
Medium, BSF-1, PMA, or BSF-1 plus PMA wasaddedto cellsprecultured in medium; medium
or PMA was added to cells precultured in BSF-1; medium or BSF-1 was added to cells
precultured in PMA; medium was added to cells precultured in BSF-1 plus PMA. In each of
these cultures, the additive(s) present in the preculture was also present in the secondary
culture because the cells were notwashed. Cellswere pulsed for4 hwith [sH]thymidine before
harvest at 24 or 48 h of secondaryculture.
PMA. Removal ofBSF-1 from cultures after 24 h inhibits entry into S phase. T
cells were precultured for 24 h with medium alone or with PMA plus BSF-1.
After 24 h, these cells were washed and recultured for 24 h with medium, PMA,
BSF-1, or PMA plus BSF-1 . These cells were then incubated with ['H]thymidine
for 16 h before harvest. Cells pretreated for 24 h with PMA plus BSF-1 do not
take up [sH]thymidine in secondary culture with medium alone, or with PMA
(Table 111). By contrast, they show striking responses to BSF-1 plus PMA and to
BSF-1 alone. This result indicates the need for BSF-1 at times beyond the first
24 h of culture. The fact that PMA did not have to be added in the second
culture does not establish a lack of requirement for PMA at that point in the
response, since PMA is poorly removed by washing. Nonetheless, because pro-
longed PMA treatment leads to a depletion ofcellular protein kinase C in many
systems (32), it is quite possible that PMA, even ifpresent, exerts relatively little
action after 24 h. Cells pretreated in medium alone make a modest response to
BSF-1 plus PMA in secondary culture, but this is far less than that of cells166 B CELL STIMULATORY FACTOR 1 ACTS ON RESTING T CELLS
TABLE III
BSF-1 Is Required Late in Initial Response to BSF-1 + PMA
Secondary culture
(24-h + 16-h pulse)
['H]Thymidine uptake
after 24-h preculture
Medium
￿
BSF-1 + PMA
cpm
RPMI
￿
2,161
￿
1,205
PMA (10 ng/ml)
￿
628
￿
1,324
BSF-1 (30 U/ml)
￿
4,846
￿
80,684
BSF-1 + PMA
￿
25,184
￿
146,690
RestingT cells were precultured at 2.5 x 105 cells/well in 24-well Costar
plates in either culture medium alone or BSF-1 (30 U/ml) plus PMA (10
ng/ml) for 24 h. The cells were then washed two times. Viable cells were
recultured, with various stimuli, at 2.5 x 104cells/well for24 handlabeled
foran additional 16 h with ['H]thymidine.
TABLE IV
Other Lymphokines Do Not ReplacePMA as a Costimulant
with BSF-1
Dense BALB/c T cells were cultured either in culture medium or in BSF-
1 (30 U/ml) at 5 x 104 cells/well with various stimuli. ['H]Thymidine
uptake was measured at between 48 and 64 h of culture.
precultured in PMA plus BSF-1, indicating that the response measured in the
latter case is not simply a response commencing at the onset of the secondary
culture. These results suggest that BSF-1 is required both in the early and later
portions of the G, phase of the first cell cycle in the response of resting T cells
to BSF-1 and PMA.
Neither IL-1, IL-3, or IFN-7 synergizes with BSF-1 or with PMA in the
stimulation of resting Tcells, nor did these agents inhibit the response to BSF-1
plus PMA (Table IV). IL-2 also failed to synergize with BSF-1 . However, IL-2
showed striking synergy with PMA, and this response was additive with the BSF-
1 plus PMA response.
BSF-1 Does Not Increase [Ca21j, in Resting T Cells.
￿
The fact that BSF-1 plus
PMA causes responses comparable to those obtained with PMA plus the calcium
Stimulant
['H]Thymidine incorporation
Without BSF-1 With BSF-I
(30 U/ml)
cpm
Medium 448 1,264
PMA (1 ng/ml) 524 53,713
IL-I (10 U/ml) 186 760
IL-1 + PMA 312 56,761
IL-2 (30 U/ml) 690 2,681
IL-2 + PMA 84,837 155,463
IL-3 (30 U/ml) 279 894
IL-3 + PMA 262 64,690
IFN--y (100 U/ml) 223 938
IFN--y + PMA 411 62,894c
m U
200
100
200
100
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FIGURE 6.
￿
BSF-1 does not cause increased [Ca211, in T cells. Dense BALB/c T cells were
loaded with Quin 2 methyl ester. Cells(6 X 106 in 3ml)were stimulated with BSF-1 (30 U/ml)
or PMA (10 ng/ml) followed by BSF-1. Con A (10 wg/ml) wasadded 6 or 5 min after BSF-1.
[Ca2']; was calculated based on fluorescence at 492 nM.
ionophores A23187 (Table I and Fig. 3) or ionomycin (data not shown) naturally
raises the possibility that BSF-1 functions in resting T cells by elevating [Ca2+];.
We measured [Ca
21], in resting T cells treated with BSF-1 alone or with BSF-1
plus PMA and found no elevation (Fig. 6). By contrast, Con A increases [Ca
211,
in both untreated and PMA-treated cells, but shows poor synergy with PMA for
T cell entry into S phase (Table I). This strongly suggests that BSF-1 costimula-
tory effects are not mediated in a manner entirely analogous to those of the
calcium ionophore.
In this communication, we show that the T cell-derived lymphokine BSF-1
synergizes with PMA in the stimulation of resting normal T cells. This response
can be obtained with highly purified populations ofsmall T cells cultured at very
low cell density (<1,000 cells/well). Furthermore, the slope relating the log of
cell number cultured and the log of the response is ^-1. Both results strongly
suggest that the costimulatory activity ofBSF-I plus PMA does notdepend upon
an accessory cell. Thus, BSF-1 and PMA, acting together, are sufficient for the
activation of resting Tcells.
Essentially all T cells are responsive to BSF-1 plus PMA, as indicated by the
finding that virtually all cells treated with this combination of stimulants have
enlarged by 24 h. A substantial fraction of the stimulated cells enter S phase.
Lyt-2+ cells incorporate more [sH]thymidine in response to BSF-1 plus PMA
than do L3T4+ cells, but we have not established that the fraction of Lyt-2+ T
cells that enter S phase in response to BSF-1 plus PMA exceeds the fraction of
L3T4+ cells that mount such a response.
T cell activation has been proposed to involve the elevation of [Ca2+]i and the
stimulation of protein kinase C (PKC)-catalyzed protein phosphorylation (33,
34). PMA and calcium ionophore stimulation of T cells is in keeping with this
concept, since PMA activates PKC (35, 36) and calcium ionophores elevate
[Ca2+]i, but it is more difficult to use this model to explain how BSF-1 synergizes
with PMA in stimulating T cells. Over short periods of time, we have observed
no elevation of [Ca2+]i in response to BSF-1 alone or to BSF-1 plus PMA. By168
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contrast, T cells do show elevation of [Ca2+]; to Con A, despite the fact that their
incorporation of [sH]thymidine in response to Con A and PMA is much poorer
than to BSF-1 plus PMA. We cannot fully exclude the possibility that BSF-1
might cause a very slow but prolonged increase in [Ca.
2+
];. However, BSF-1 also
fails to cause increases in [Ca21], in B cells, and some BSF-1 effects in B cells can
be obtained in calcium-deficient media (37). These results strongly suggest that
elevation of [Ca2+1, is not required for T cell activation in response to BSF-1 plus
PMA. The lack of requirement for [Ca2+]; elevation in lymphocyte activation is
not without precedent, since the response of B cells to lipopolysaccharide (LPS)
is not associated with increased [Ca2+]; or with increased inositol phospholipid
metabolism (38, 39). However, an important difference here is that the LPS
response in B cells also appears to be independent of PKC (Mizuguchi and Paul,
unpublished observations), whereas BSF-1 effects on T cells depend upon PMA
and, presumably, upon protein phosphorylation catalyzed by PKC. Thus, the
capacity of BSF-1 plus PMA to stimulate efficient, accessory cell-independent
activation of resting T cells raises questions about how accessory cells act in T
cell stimulation and about the central role of [Ca2+]; elevation in the responses.
One possible explanation for this result is that the response to PMA plus A23187
requires both an induction of sensitivity to lymphokine, such as IL-2 or BSF-1,
and the stimulation of lymphokine production. In the response to BSF-1 plus
PMA and to IL-2 plus PMA (discussed below), it is possible that only sensitivity
to lymphokine need be induced, since BSF-1 or IL-2 is supplied exogenously.
This leads to the conclusion that induction of sensitivity to lymphokine may be
due to the action of PKC (or possibly through the action of another cellular
target of PMA) without any requirement for increase in [Ca2+];. An important
issue is to identify the natural ligand(s) that replaces PMA in its synergy with
BSF-1 and with IL-2 . Although receptor crosslinking agents are obvious candi-
dates, their role in replacing PMA has not been established.
In the course of this work, we also noted that PMA plus IL-2 caused resting
T cells to become activated and to enter S phase. Like BSF-1, IL-2 is required
during the first 24 h of the response (Hu-Li and Paul, unpublished observations)
suggesting that it acts on Go or, more likely, early G, T cells. One possible mode
of stimulation by this combination of agents would be the induction by PMA of
a small number of IL-2 receptors and the upregulation of receptor number
through the action of IL-2 (40) . Such cells might then be stimulated to enter S
phase by the binding of IL-2 to the heightened number of receptors present in
late G, .
BSF-1 has been shown to act directly on resting B cells (2, 3, 16-18). We show
here that BSF-1 can act on resting T cells. Thus, the addition of BSF-1 to resting
T cells causes striking increases in cell viability detectable by 2 d and persisting
for periods of 5 d or more without any evidence of cell division. In addition,
BSF-1 is required early in the costimulation of T cells; delaying the addition of
BSF-1 by 24 h to cells cultured with PMA delays entry into S phase by 24 h.
This strikingly parallels theaction of BSF-1 on B cells, wheredelaying its addition
to B cells cultured with anti-IgM delays their entry into S phase (18).
These results indicate that BSF-1 acts on resting T cells and thus raise the
question of how BSF-1 may regulate T cell growth. Two major possibilities exist.HU-LI ET AL.
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BSF-1 may function by acting on resting T cells, together with PMA, to induce
IL-2 receptor expression and IL-2 production. This could be restated to say that
BSF-1 plus PMA jointly act as a competence factor for resting (Go) T cells and
that IL-2 acts as in late G, to stimulate entry into S phase (i.e., as a progression
factor). We have already proposed a similar model for the action of BSF-1 on B
cells, where we suggest that BSF-1 and anti-IgM jointly act as a Go and/or early
G, competence factor (18). Recently, BSF-1 has been shown to enhance the
responses of some mast cell lines to IL-3 (14). Peschel, Paul, Ohara, and Green
(manuscript submitted for publication) have shown that BSF-1 synergizes with
recombinant erythropoietin and with IL-1 for the formation of megakaryocytic
colonies in softagar, with erythropoietin for the formation oferythroid colonies,
and with granulocyte colony-stimulating factor for the formation ofgranulocytic
colonies. Based on these observations, we suggest that BSF-1 may act as a
competence factor (or a competence cofactor) for virtually all hematopoietic
lineage cells.
A second possibility is that BSF-1 may act both as a lymphocyte activating
factor and as a progression factor. According to this concept, rather than
stimulating T cell responses by inducing IL-2 receptor expression and IL-2
production, BSF-1 causes resting T cells to enter S phase by acting with PMA to
activate these cells and torender them sensitive to the growth stimulatingactivity
of BSF-1 itself. BSF-I would thus act as a cocompetence factor and as a
progression factor. Indeed, it has been shown that many T cell lines fail to
secrete IL-2 but do produce BSF-1 (41). The growth of one such line, D10, in
response to antigen and antigen-presenting cells is inhibited by monoclonal
antibodies to BSF-1, but not by antibody to the IL-2 receptor (42). Similarly,
Fitch and colleagues (43) have described a cloned T cell line the growth of which
was stimulated by antigen and antigen-presenting cells and did not require the
addition of IL-2. Nevertheless, this line did not secrete detectable IL-2; IL-2
mRNA was not found by hybridization to dot blots, and antibody to the IL-2
receptor did not block its responses to antigen and antigen-presenting cells.
These results suggest that lymphokines other than IL-2 can act as T cell
progression factors. Indeed, finding that an anti-IL-2 antibody (S4B6.1) fails to
inhibit responses to BSF-1 plus PMA suggests that IL-2 is not required for all
growth in response to BSF-1 plus PMA.
In our opinion, understanding the mode of action of BSF-1 on T cells and
relating it to that of IL-2 is a goal of considerable importance. Direct studies
aimed at this issue are now in progress in our laboratory.
Finally, we note that IFN-y does not block the actions of BSF-1 plus PMA on
resting T cells. IFN-y has been shown to be a powerful inhibitor ofthe action of
BSF-1 on resting B cells, blocking both preparation to enter S phase (44) and
induction ofclass II molecules (45). This result indicates that the inhibitory effect
of IFN-y is cell type-specific and not general.
Summary
Resting T cells proliferate in response to B cell stimulatory factor 1 (BSF-1 ;
interleukin 4) plus phorbol myristate acetate (PMA). This response is obtained
with highly purified T cells and is density independent, suggesting that accessory170
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cells are not required. Both L3T4+ and Lyt-2+ T cells respond to BSF-1 plus
PMA.
Although BSF-1 alone does not cause T cell proliferation, it maintains the
viability of small, dense T cells, indicating that it acts on resting T cells.
Furthermore, BSF-1 is required early in the proliferative response of resting T
cells to BSF-1 plus PMA, further supporting the concept that it acts on Go or
early G, cells. However, BSF-1 is also needed late in the first round of division
of T cells stimulated with BSF-1 plus PMA . Removing BSF-1 at 24 h of
stimulation prevents entry into S phase . These results indicate that BSF-1 is
involved in both the induction of competence and in the progression phases of
T cell division.
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